Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19

TOP - March 2022 Vol 15, No 2 - COVID-19 & Cancer

According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment. These results were presented by Alessio Cortellini, MD, Consulting Medical Oncologist and Visiting Researcher, Department of Surgery and Cancer, Imperial College, London, England, and Researcher, Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, Italy, at the virtual European Society for Medical Oncology Congress 2021.

“It is known that 13% to 60% of COVID-19 patients in the general population can experience long-term sequelae, and 60% to 80% of patients with cancer outlive COVID. But there are unanswered questions about the long-term impact of COVID on patients with cancer that this study sought to address,” Dr Cortellini stated.

Study Details

The OnCOVID registry gathered data on a total of 2795 patients with cancer who were treated at 35 different institutions across 6 European countries from February 2020 to February 2021. Dr Cortellini presented results from 1557 patients with cancer who underwent reassessment after they recovered from COVID-19 to characterize the prevalence and impact of COVID-19 sequelae, and whether systemic anticancer therapy could be resumed.

At a median post–COVID-19 follow-up of 128 days, long-term sequelae were associated with a 76% increase in the risk for death in an analysis adjusted for sex, age, comorbidities, tumor characteristics, anticancer therapy, and COVID-19 severity.

Among the 1557 patients with cancer who had recovered from COVID-19, 234 (15%) suffered at least 1 post–COVID-19 sequelae. The most frequently reported sequelae included respiratory symptoms (49.6%), fatigue (41%), neurocognitive issues (7.3%), and weight loss (5.6%).

Factors associated with an increased risk for long-haul COVID-19 included being male, age ≥65 years, the presence of ≥2 comorbidities, current or former smoking history, and increased rates of previous complicated COVID-19, requiring therapy for COVID-19, and requiring hospitalization for COVID-19.

Of the 471 patients who were being treated with systemic anticancer therapy at the time of COVID-19 diagnosis, long-haul COVID-19 was more prevalent among those who discontinued anticancer care. When patients were reassessed after COVID-19, 14.8% required permanent discontinuation of cancer treatment, which was associated with a 3.5-fold increase in the risk for death. The most common reason for discontinuation of anticancer therapy was worsening performance status, which was reported in 61.3% of patients.

Among patients who required dose adjustments and resumed anticancer therapy (37.8%), survival was not compromised. The main factors that led to dose or regimen adjustments were avoiding hospital attendance (25.8%), immunosuppression (50%), or adverse events (19.1%). Anticancer therapy was unchanged in 9.6% of patients post–COVID-19.

“OnCOVID data suggest that improved awareness, prevention, recognition, and early treatment of COVID-19 sequelae in patients with cancer are important steps toward optimal management,” Dr Cortellini concluded.

Related Items
Multicancer Early Detection Blood Test May Change Cancer Screening Paradigms
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Determination Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Multiple Myeloma
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Promising New Approach to Treating Patients with Desmoid Tumors
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in COVID-19 & Cancer
Neoadjuvant Chemoimmunotherapy Shows Promise in Advanced Ovarian Cancer
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Ovarian Cancer
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Last modified: March 30, 2022